This allows you to stay within a safe, effective dosage range without wasting money on unabsorbed nutrients
AOD-9604 failed Phase 2 not due to safety concerns but because the magnitude of fat loss versus placebo, while statistically significant, was too modest to meet the efficacy threshold for a standalone obesity treatment
By the fifth and sixth decades of life, GH pulse amplitude and total daily GH secretion are significantly reduced compared to younger adults, with corresponding reductions in IGF-1
Athletes recovering from intense training or competition benefit most from IV infusions for athletic recovery
Over the past several years, the company repositioned entirely around pemvidutide, its balanced dual GLP-1/glucagon receptor agonist for obesity and liver disease
All-in-one, science-backed, and made for how you actually feel